The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD (the “Company”) hereby informs that from 11 July 2013 up to and including 17 July 2013 the Company bought 31378 own shares representing 0.024% of the share capital of the Company, to the total value of BGN 96443.15 on the Bulgarian Stock Exchange. The average price per share was BGN 3.07.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4476884, representing 3.39% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 18 July 2013 up to and including 24 July 2013 the Company bought 161424 own shares representing 0.12% of the share capital of the Company, to the total value of BGN 528930.57 on the Bulgarian Stock Exchange. The average price per share was BGN 3.277.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4638308, representing 3.51% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 25 July 2013 up to and including 31 July 2013 the Company bought 276414 own shares representing 0.21 % of the share capital of the Company, to the total value of BGN 920042.05 on the Bulgarian Stock Exchange. The average price per share was BGN 3.33.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4914722, representing 3.72% of the share capital of the Company.
Sopharma AD (the “Company”) announces that: Sopharma AD bought 1000 shares, representing 0.21% of the capital of Maritzatex AD and as a result of this transaction the Company has crossed the threshold of 10 % of the capital of Maritzatex AD and now owns 10.12% of the capital of the latter.
The date of registration of the transaction with the Central Depository is 31 July 2013.
Sopharma AD (the “Company”) notifies that for July 2013 the Company realized a decrease of sales revenues of 16 % compared to the same period of 2012, including 10% decrease of domestic sales and 19% decrease of export sales.
During the past seven months Sopharma AD recorded a decrease of sales revenues of 2%, including 5% increase of domestic sales and 4% decrease of export sales compared to the same period of 2012.
SOPHARMA AD (the “Company”) hereby informs that from 1 August 2013 up to and including 7 August 2013 the Company bought 185367 own shares representing 0.14 % of the share capital of the Company, to the total value of BGN 615590.99 on the Bulgarian Stock Exchange. The average price per share was BGN 3.32.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 5100089, representing 3.86% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 8 August 2013 up to and including 14 August 2013 the Company bought 19,523 own shares representing 0.014 % of the share capital of the Company, to the total value of BGN 64,166.87 on the Bulgarian Stock Exchange. The average price per share was BGN 3.29.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5,119,612, representing 3.88% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 15 August 2013 up to and including 21 August 2013 the Company bought 82939 own shares representing 0.063 % of the share capital of the Company, to the total value of BGN 272986.21 on the Bulgarian Stock Exchange. The average price per share was BGN 3.29.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5202551, representing 3.94% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 22 August 2013 up to and including 28 August 2013 the Company bought 7616 own shares representing 0.006 % of the share capital of the Company, to the total value of BGN 25316.48 on the Bulgarian Stock Exchange. The average price per share was BGN 3.324.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5210167, representing 3.95% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 29 August 2013 up to and including 4 September 2013 the Company bought 5 250 own shares representing 0.004 % of the share capital of the Company, to the total value of 16 922 BGN on the Bulgarian Stock Exchange. The average price per share was 3.22 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 213 417, representing 3.95% of the share capital of the Company.